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Abstract
CD26 is a T cell activation marker consisting in a type II transmembrane glycoprotein with
dipeptidyl peptidase IV (DPPIV) activity in its extracellular domain. It has been described
that DPPIV inhibition delays the onset of type 1 diabetes and reverses the disease in non-
obese diabetic (NOD) mice. The aim of the present study was to assess the effect of
MK626, a DPPIV inhibitor, in type 1 diabetes incidence and in T lymphocyte subsets at cen-
tral and peripheral compartments. Pre-diabetic NOD mice were treated with MK626. Diabe-
tes incidence, insulitis score, and phenotyping of T lymphocytes in the thymus, spleen and
pancreatic lymph nodes were determined after 4 and 6 weeks of treatment, as well as alter-
ations in the expression of genes encoding β-cell autoantigens in the islets. The effect of
MK626 was also assessed in two in vitro assays to determine proliferative and immunosup-
pressive effects. Results show that MK626 treatment reduces type 1 diabetes incidence
and after 6 weeks of treatment reduces insulitis. No differences were observed in the per-
centage of T lymphocyte subsets from central and peripheral compartments between
treated and control mice. MK626 increased the expression of CD26 in CD8+ T effector
memory (TEM) from spleen and pancreatic lymph nodes and in CD8
+ T cells from islet infil-
tration. CD8+TEM cells showed an increased proliferation rate and cytokine secretion in the
presence of MK626. Moreover, the combination of CD8+ TEM cells and MK626 induces an
immunosuppressive response. In conclusion, treatment with the DPPIV inhibitor MK626
prevents experimental type 1 diabetes in association to increase expression of CD26 in the
CD8+ TEM lymphocyte subset. In vitro assays suggest an immunoregulatory role of CD8
+
TEM cells that may be involved in the protection against autoimmunity to β pancreatic islets
associated to DPPIV inhibitor treatment.
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Introduction
Type 1 diabetes (T1D) results from the progressive destruction of insulin-producing pancreatic
β-cells by CD4+ and CD8+ T cells [1]. Most self-reactive T cells are deleted by central tolerance
mechanisms in the thymus; however even if central tolerance is highly efficient, a number of
self-reactive cells escape from this barrier. In the non-obese diabetic (NOD) mouse, which
spontaneously develops autoimmune T1D similar to the human disease, central and peripheral
tolerance defects have been described [2].
CD26 is a type II transmembrane glycoprotein with dipeptidyl peptidase IV (DPPIV) activ-
ity in its extracellular domain. CD26 is constitutively expressed on the surface of many cell
types, including immune cells [3], and a soluble form is also present in plasma. CD26 has been
extensively characterized and multifunctional effects have been demonstrated [4]. The protein
has at least 5 functions: a) serine protease, b) receptor for adenosine deaminase and CD45, c)
co-stimulatory protein, d) adhesion molecule for collagen and fibronectin and e) involvement
in apoptosis [5]. The most prominent and well-known biological properties are those related to
signal transduction ability as a co-stimulatory molecule and proteolysis [6]. CD26 is preferen-
tially expressed on a specific population of T lymphocytes, the subset of CD4+CD45RO+ mem-
ory T cells, and is up-regulated following T cell activation [7]. The enzymatic activity of CD26
appears to be very important in enhancing cellular responses to external stimuli being neces-
sary for its co-stimulatory function [8]. It has recently been described that caveolin-1 in antigen
presenting cells (APCs) is a binding protein for CD26. Their interaction results in the up-regu-
lation of CD86 in the APC and enhances T cell co-stimulation [9]. The same group demon-
strated that the catalytic site of CD26 is located in the pocket structure involved in the
caveolin-1 scaffolding domain.
In CD4+ T cells, high CD26 cell surface expression correlates with the production of
Th1-type cytokines and high transendothelial migratory activity, while CD26+ T-helper cells
stimulate antibody synthesis in B cells [10]. In CD8+ T cells, CD8+CD26bright T cell subset has
recently been characterized as early effector memory T cells and reported to exert a cytotoxic
effect, preferentially via B cells, TNF-α, IFN-γ and the Fas ligand [11]. In T1D patients, CD26
expression is reduced in the peripheral blood of CD8+ T cell subset [12]. CD26 is also thought
to be a thymic maturation marker and its impairment has remarkable effects on lymphocyte
composition, memory T cell generation and thymic emigration patterns [13,14].
Inhibition of DPPIV/CD26 suppresses antigen-stimulated T cell proliferation and cytokine
production, thus suggesting a potential application for DPPIV inhibitors as immunomodula-
tory drugs in autoimmune diseases [15]. In animal models of autoimmune diseases, such as
experimental autoimmune encephalomyelitis, in vivo inhibition of CD26 delays and attenuates
the severity of the disease [16]. In this model, DPPIV inhibitors suppress IFN-γ, IL-4 and
TNF-α production by antigen-stimulated CD4+ T cell clones [7]. In animal models of T1D,
pre-treatment with a DPPIV inhibitor (sitagliptin) improves islet transplantation in both strep-
tozotocin-induced diabetic mice [17] and in NODmice [18]. In the latter, sitagliptin protects
the islet graft through the modulation of CD4+ T cell migration and reduction of insulitis [19].
Moreover, DPPIV inhibition delays the onset of T1D [20] and reverses the disease in NOD
mice [21]. Latent autoimmune diabetes in adults (LADA) is a form of less severe autoimmune
diabetes than T1D. It has been recently reported that treatment with a DPPIV inhibitor in
LADA patients attenuates the rate of decline of C-peptide levels, thus contributing to the main-
tenance of β-cell function [22]. Also, in the clinical setting, it has been described that the risk of
autoimmune diseases is lower in those type 2 diabetes (T2D) patients who are being treated
with a DPPIV inhibitor [23].
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To our knowledge, the potential for modification of several T lymphocyte subsets from both
the thymus and periphery with a DPPIV inhibitor in NODmice, and its possible contribution
to immune tolerance, have not been previously studied. The present work evaluates the effect
of the DPPIV inhibitor MK626 in experimental T1D incidence and in thymic and peripheral T




In vivo experiments were performed in strict accordance with the recommendations of the
Guide for the Care and Use of Laboratory Animals of the Generalitat de Catalunya, Catalan
Government and the Principles of laboratory animal care (NIH pub.85–23 revised 1985; http://
grants1.nih.gov/grants/olaw/references/phspol.htm). The protocol was approved by the Com-
mittee on the Ethics of Animal Experiments of the Germans Trias i Pujol Research Institute
(Permit number: DMAH5928).
Mice
Wild-type NODmice were obtained from our colony established with mice from the Jackson
Laboratory (Bar Harbor, ME, USA). Only females were used for this study. Mice were kept
under specific pathogen-free conditions in a 12 h dark/12 h light cycle with food and water ad
libitum. At the end of the experiments, mice were sacrificed by cervical dislocation.
Reagents and diets
MK626, a DPPIV inhibitor analog of des-fluoro-sitagliptin (kindly donated by Richard D.
Carr, MSD Research Laboratories, New Jersey, USA), was administered daily in the diet (21
mg/kg, Research Diets, Inc. New Brunswick, NJ) for in vivo studies. Moreover, MK626, from
the same source as for in vivo experiments, was used for in vitro studies.
In vivo effect of MK626 treatment
NOD/LtJ mice were placed on either a normal chow diet (Research Diets, Inc. New Brunswick,
NJ) or a diet containing the DPPIV inhibitor MK626. To determine the effect of MK626 in
lymphocyte subsets, pre-diabetic mice (6–8 weeks of age) were treated during 4 and 6 weeks (5
mice/time-point). As control, untreated mice were used (5 mice/time-point). Spleen, pancre-
atic lymph nodes (PLNs) and pancreas were harvested for immunological analyses. All experi-
ments were replicated twice.
To determine the in vivo effect of MK626 in T1D development, 15 NODmice at 6–8 weeks
of age were fed an MK626-containing diet. A control group of NODmice (n = 15) was fed a
normal chow diet. Mice were followed for diabetes onset until they reached 30 weeks of age.
Incidence of the disease was determined at the end of the follow-up period.
Mice were monitored daily for urine glucose using Glucocard strips (Menarini, Barcelona,
Spain). Mice with glycosuria were confirmed new-onset diabetic when successive blood glucose
level was higher than 300 mg/dl after fasting for 2 hours (AccuCheck, Roche Diagnostics, Indi-
anapolis, IN).
DPPIV activity assessment
Plasma DPPIV enzymatic activity in mice receiving MK626 treatment and in control group
was assessed by continuous fluorometric reaction (Edmonson SD, et al 2006) at 2, 4 and 6
DPPIV/CD26 in the Prevention of Type 1 Diabetes
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weeks after treatment initiation (4 mice in each group/time-point). Briefly, the substrate Gly-
Pro-Aminomethylcoumarin (AMC), containing a proline in a position cleaved by DPPIV,
releases pro-AMC, generating a high fluorescent emission (RFU). The reaction substrate con-
tains 50% plasma, 50 μMGly-Pro-AMCand buffer (100 mMHepes pH 7.5, 0.1 mg/ml BSA) in
a total volume of 50 μl. AMC liberation was monitored at 460 nm at 37°C (Viroskand Fluo-
rometer, Thermo Electron, Germany). Data are reported as percent of inhibition.
Insulitis score
The degree of islet infiltration by leukocytes (insulitis) was analyzed at 2, 4 and 6 weeks after
treatment. Briefly, pancreases from 4 mice in each group were snap frozen in an isopentane/
cold acetone bath. Cryosections of 5 μmwere obtained at 5 non-overlapping levels. The sec-
tions were stained with hematoxylin and eosin (H&E) and analyzed by two independent
observers. Each observer assessed a minimum of 40 islets per animal. Insulitis was scored as
described elsewhere [24]: 0, no insulitis; 1, peri-insular; 2, mild insulitis (<25% of the infil-
trated islet); 3, moderate insulitis (25–75% of the infiltrated islet); 4, severe insulitis (>75% islet
infiltration).
Tissue processing steps
Spleens and thymi were obtained at 4 and 6 weeks after treatment, whereas PLNs were
obtained at 4 weeks. Thymic tissue was processed by enzymatic digestion. Briefly, small pieces
of tissue were cut with a sterile blade, placed in 2% FCS-RPMI + 2 mg/ml Collagenase P (Boeh-
ringer Manheim, IN, USA) and incubated for 20 minutes at 37°C. The thymocyte suspension
was washed and filtered using a 70-μm strainer and then re-suspended in Stain Buffer (BD Bio-
science, San Jose, CA). The spleen was processed by mechanical disruption and mononuclear
cells were isolated from the cell suspension by density gradient centrifugation using Lympho-
lyte Mouse (Cedarlane Labs, Burlington, Canada), at 800g for 20 minutes at RT, and cells were
then washed and filtered using a 70-μm strainer. Cells were re-suspended in Stain Buffer (BD
Bioscience). PLNs were removed from mice and put in Phosphate Buffer. Then, PLNs were
mechanically disrupted and re-suspended in a single cell suspension before the staining.
Flow Cytometry
Thymocytes and peripheral T lymphocyte subsets from NOD, with or without MK626 treat-
ment, were stained using an optimized panel of fluorochrome-conjugated monoclonal antibod-
ies (mAb) (shown in Table 1). Specifically for T cell regulatory subset, T cells from spleen and
PLNs were stained with anti-CD4-APCCy5.5 (BD), anti-CD25-PerCP (BD) and anti-Fox-
P3-eF450 (EBiosciences). Also T cells were stained with anti-CD8-V500 (BD), anti-PD1-PeCy7
(BD) and anti-CD122-biotin (BD). SA-APC (BD) was used as a secondary antibody. Analyses
were run on a FACS Canto II flow cytometer (BD).
GLP-1 determination
Plasma was obtained at 2, 4 and 6 weeks after treatment (4 mice/time-point). GLP-1 was deter-
mined using the active GLP-1 ELISA kit (Millipore, Billerica, MA), specific for GLP-1 (7–36)
amide form, the main form of circulating biologically active GLP-1.
The experiment was replicated twice.
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Plasma TGF-β concentration
TGF-β levels were quantified in serum at 4 and 6 weeks (5 mice/time-point) in MK626-treated
and control NOD mice, using a specific Human/Mouse TGF-β1 ELISA Ready-SET-Go kit (e-
Bioscience, USA). The experiment was replicated twice.
Phenotyping of pancreatic islet infiltrate
To characterize islet infiltrating leukocytes and to determine their CD26 expression, pancreases
from treated (n = 4) and control NODmice (n = 4) were obtained 4 weeks after treatment. The
experiment was replicated twice. Briefly, pancreases were perfused with collagenase (Collage-
nase CLS-4; Worthington Biochemical, Lakewood, NJ) through the common bile duct as
described [25]. Pancreases were removed and incubated at 37°C for 15 min. After digestion,
collagenase was neutralized with HBSS medium and the digested tissue was placed into a petri
dish. Islets were hand-picked, mechanically homogenized and filtered with a 70 μm cell strainer
to obtain a single cell suspension. For the identification of cell subsets, cell suspension was
stained with a primary antibody Rat anti-mouse CD8 (clone Lyt-2.2; MyBiosource, San Diego,
CA). After a single wash, a secondary antibody Goat anti-Rat FITC (SouthernBiotech, Bir-
mingham, AL) was used. Finally, a third stage staining was performed with an anti-CD3 V450
(BD), anti-CD4 APC-Cy7 (BD) and anti-CD26 PE antibody (BioLegend, San Diego,
California).
T lymphocyte stimulation assay
Spleens were removed from treated (n = 5) and control mice (n = 5) and erythrocytes were
lysed in 0.87% ammonium chloride. From each group 3x107 splenocytes were firstly stained
with biotinylated anti-CD62L (clone MEL14-H2.100, Miltenyi Biotech) and with the Pan T
Isolation Kit II (Miltenyi, 130-095-130). Splenocytes were passed through a Magnetic LS
MACS column (Miltenyi 130-042-401) and the unbound fraction corresponding to Effector
memory (TEM) T lymphocytes was isolated. A second stain was performed to purify CD8
+ TEM
lymphocytes. Then, cells obtained were stained with an anti-CD4 antibody, clone L3T4 (Milte-
nyi Biotech) and passed through another LS column. The unbound eluted fraction, corre-
sponding to the CD8+ TEM lymphocytes subset, was finally used for the proliferation assays.
Table 1. List of mAb used for the analysis of lymphocyte subsets. BD (BD Biosciences, San Jose, CA); eB (eBioscience, San Diego, CA); DN: double
negative; DP: double positive; SP: single positive; T CM: central memory T cell; T EM: effector memory T cell; CD26 expression was assessed in all lymphocyte
subsets.
Lymphocyte subset Phenotype Marker





















CD4+T regulatory cells CD4+CD25+FoxP3+
CD8+T regulatory cells CD8+PD1+CD122+
doi:10.1371/journal.pone.0142186.t001
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Stimulus consisted of 1 μg/ml of anti-CD3 monoclonal antibody (clone 145-2C11, BD Biosci-
ence) plated 24 hours before the assay. 5x104 CD8+ TEM lymphocytes from treated or control
mice were cultured in round bottom 96 wells during 72 hours. Cells were pulsed with 1 μCi of
[3H]thymidine in the last 18 hours of the assay. Cells were harvested (Harvester 96, Tomtec
Inc., Hamden, CT) and analyzed using a scintillation counter (1450 Microbeta, TriluxWallac,
Turku, Finland). T cell proliferation was expressed as counts per minute (c.p.m). After 54
hours of T lymphocyte stimulation, supernatants were collected and cytokine production was
assessed by flow cytometry using the Bead Array-CBA kit (BD Bioscience), which measures IL-
2, IL-4, IL-6, IL-10, IL-12, IL-17, IFN-γ and TNF-α concentration. Data were analysed using
the CBA software. TGF-β levels were quantified using a specific Human/Mouse TGF-β1 ELISA
Ready-SET-Go kit (e-Bioscience, USA). The experiments were replicated twice.
Biomarkers of β-cell regeneration by qRT-PCR
To determine if DPPIV inhibition allows specifically β-cell regeneration, we investigated
whether MK626 alters the expression of genes encoding β-cell autoantigens. As control, gluca-
gon gene expression was also evaluated to assess α-cell mass increase. CD45 (lymphocyte com-
mon antigen) expression was used as a marker of T-lymphocytic infiltrate. Total RNA was
extracted using the kit RNeasy Micro (QIAGEN, Venlo, Limburg, The Nederlands) from
whole pancreases from 5 control and 5 MK626-treated animals after 4 weeks of treatment.
Prior to RNA isolation, cryosections of frozen pancreata were mechanically disaggregated
when thawed. MinElute Spin Columns were used to extract RNA from samples following man-
ufacturer's instructions. RNA integrity and concentration was measured using 2200 TapeSta-
tion (Agilent Technologies, Santa Clara, CA). cDNA synthesis reactions were carried out using
random hexamers (0.5 μg/μl, BioTools, Valle de Tobalina, Madrid, Spain) and reverse tran-
scriptase Moloney-murine-Leukaemia-virus (M-MLV) (200 U/μl, Promega, Madison, WI),
and samples were incubated for 60 minutes at 37°C. Finally, qRT- PCR were performed under
Taqman universal assay on the Light Cycler 480 system using the following TaqMan assays:
Insulin II (Ins2) (Mm00731595_gH), Islet amyloid polypeptide (Iapp) (Mm00439403_m1), Glu-
cagon (Gcg) (Mm01269055_m1) and CD45 (Mm01293577_m1). House-keeping gene Gapdh
(Mm99999915_g1) expression was also assessed in order to normalize the expression of the
target genes to that of the housekeeping gene, as described in the relative quantification method
(2-ΔCp) [26], and was referred as arbitrary units.
T lymphocyte suppressive assay
MK626 was diluted in water and tested in vitro at 10 μM to determine the effect on the viability
of splenocytes, as a previous step for the suppression assay. Briefly, splenocytes were obtained
after mechanical disruption of spleen and cultured in presence of different concentrations of
MK626. Viability was assessed at 2, 24 and 48 hours by annexin V-PE and 7-aminoactinomy-
cin D labelling (7aad) (BD Pharmingen, San Diego, CA).
To assess whether MK626 increases CD8+ TEM lymphocytes’ immunosuppressive function,
the putative regulatory T lymphocytes and effector T lymphocytes obtained from non-diabetic
NODmice at 10–12 weeks of age were differentially labelled with intracellular fluorescent dyes
CellTrace Violet (CTV, Molecular Probes, Molecular Probes, Invitrogen, Thermo Fisher Scien-
tific Inc) and carboxyfluorescein diacetate, succinimidyl ester (CFSE, Molecular Probes, Invi-
trogen, Thermo Fisher Scientific Inc, Waltham, MA), respectively. Autologous suppression
assays were established in 96-well plates with 4x104 CFSE-labelled splenic T lymphocytes and
4x103 autologous insulin-loaded mDCs, as antigen presenting cells (APCs), cocultured with
CD8+ TEM lymphocytes at different ratios (1:0.5, 1:1 and 1:2, being T cell:CD8 TEM), in
DPPIV/CD26 in the Prevention of Type 1 Diabetes
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presence or absence of MK626 (10μM). Splenic T lymphocytes were purified with the Pan T
Isolation Kit II (Miltenyi) through a Magnetic LS MACS column (Miltenyi). CD8+ TEM lym-
phocytes were purified as detailed before (see T lymphocyte stimulation assay). Insulin-loaded
mature DCs (mDCs) were obtained as previously described [27]. Briefly, immature DCs
(iDCs) were generated in vitro from bone marrow progenitors of NODmice in culture medium
containing GM-CSF (1000 U/ml; Prospec, Rehovot, Israel). iDCs were cocultured in presence
of insulin (20μg/ml, Sigma) for 2 hours and stimulated with lipopolysaccharide (LPS, 100 ng/
ml; Sigma) for 24 hours to obtain mDCs. Finally, after 3 days of coculture, cells were harvested
and data were acquired by flow cytometry (FACSCanto II) and analysed using the FlowJo soft-
ware (Tree Star, Ashland, OR). Dead cells were excluded from the analysis using 7aad (BD
Pharmingen).
Statistical analysis
Data analysis was performed by applying a three-way ANOVA for every continuous variable,
controlling by group (two levels, control and treatment), week (two levels, week 4 and week 6)
and replicate (two levels, replicate 1 and 2). The replicate was considered a block factor, not
affecting any interaction including replicate factor; thus the group-per-week interaction was
the only interaction factor considered. Observations with a Studentized residual (in absolute
value) greater than 3 were considered outliers and were removed from the analysis. This situa-
tion usually affected just one individual. Post-hoc analyses using Tukey’s HSD were performed
to detect differences between the combinations of factors per group and week. Otherwise,
Mann-Whitney U-test was applied. Kaplan-Meier log-rank analysis was used to compare the
incidence of diabetes between different groups. A p-value 0.05 was considered significant.
Statistical analysis was performed using the Prism 5.0 software (GraphPad software Inc., San
Diego, CA) and “R” software version 3.0 (www.rproject.org).
Results
DPPIV inhibitor MK626 reduces the incidence of diabetes and the
insulitis score
We first evaluated the effect of an MK626-containing diet. The percentage of plasma DPPIV
activity was reduced by more than 90% in the MK626-treated group, and this inhibition was
maintained throughout the study period (week 4: 95.82%; week 6: 92.44%.), thus confirming
that DPPIV activity was mostly inhibited in the MK626-administered mice (S1A Fig). Plasma
levels of active GLP-1 displayed a biological increase in the MK626-treated mice, although sta-
tistically non-significant (S1B Fig).
At the end of the follow-up period of the incidence study at week 30, T1D incidence was sig-
nificantly decreased in MK626-treated mice (37%) when compared with control mice (68%),
(p = 0.05, Fig 1A). Thus, a 31% reduction in the incidence of diabetes was achieved in the
treated group. In view of the reduced incidence of diabetes in MK626-treated mice, we next
aimed to determine the impact of MK626 on insulitis score at 2, 4 and 6 weeks of treatment.
The insulitis score was significantly lower in treated mice than in controls after 6 weeks of
treatment (0.83 ± 0.27 vs. 1.52 ± 0.26, respectively; p = 0.022) (Fig 1B), whereas no differences
were observed between groups at week 2 and at week 4 of treatment. Representative images of
islets from haematoxylin and eosin-pancreatic cryostat sections from treated and control mice
at 6 weeks after treatment are showed in the lower panel of Fig 1B. Moreover, analysis of the
percentage of islets classified in each of the five infiltration categories showed that in 6 weeks-
treated mice most of the islets remained free of insulitis or with peri-insulitis, whereas in the
DPPIV/CD26 in the Prevention of Type 1 Diabetes
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Fig 1. DPPIV inhibitor MK626 decreases T1D incidence and reduces the insulitis score in NODmice. A) Cumulative incidence (percentage) of
diabetes in NODmice treated with MK626 (black circles, n = 15) and in the control group (white circles, n = 15). Significant differences were found when
compared MK626-treated mice versus control group (*p0.05, Kaplan-Meier log-rank analysis). B) Insulitis score from treated and untreated mice at each
time-point. Pancreases from 4 mice/group were analyzed by two independent observers at 2, 4 and 6 weeks after treatment. Insulitis score was significantly
lower in treated mice than in controls after 6 weeks of treatment. Results are expressed as mean ± SEM (*p0.05, Mann-Whitney test). Lower panel:
sections of pancreas from haematoxylin and eosin illustrating islets taken from a treated and control mice at 6 weeks. c) Percentage of islets in each of the
five infiltration categories in treated and control mice at 2, 4 and 6 weeks: White = 0, no insulitis; Dotted = 1, peri-insular; Striped = 2, mild insulitis (<25% of
the infiltrated islet); Squared = 3, moderate insulitis (25–75% of the islet infiltrated); Black = 4, severe insulitis (>75% islet infiltration).
doi:10.1371/journal.pone.0142186.g001
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control group most of the islets were scored with a severe degree of insulitis (Fig 1C). Insulitis-
free islets were more than 50% in MK626-treated mice at 6 weeks.
These results strongly suggest that DPPIV/CD26 inhibition by MK626 prevent T1D
through impairment of islet autoimmune attack.
MK626 treatment does not modify plasma TGF-β levels
The effect of MK626 on serum levels of TGF-βwas evaluated at 4 and 6 weeks after treatment.
Although plasma TGF-β levels displayed a biological increase in MK626-treated mice compared to
control mice, the difference was not statistically significant at any of the study’s time-points (Fig 2).
MK626 increases CD26 expression in CD8+ Effector memory T cells
To investigate the potential mechanisms by which the DPPIV inhibitor MK626 induced a
reduction in T1D incidence and insulitis score, we aimed to determine whether treatment with
Fig 2. Serum TGF-β concentration from NODmice after MK626 treatment. Serum level of TGF-β from
control (white bars) and treated (black bars) after 4 and 6 weeks of treatment. Results are expressed as
mean ± SD from 10 mice/time-point. No statistical differences were observed between groups (Mann-
Whitney test).
doi:10.1371/journal.pone.0142186.g002
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MK626 was associated with changes in T cell subsets from both the thymus and peripheral
compartments (spleen and PLNs) and/or in their expression of CD26, which could contribute
to the development of immune tolerance.
1. Thymus: Treatment with MK626 does not modify thymocyte subsets. Because CD26
has been shown to play a role in the differentiation and maturation of thymocytes, the effect of
MK626 on the percentage of thymocytes subsets was next studied. No significant changes in
the percentages of single positive (SP) CD4+ and SP CD8+, double positive (DP) CD4+CD8+
and double negative (DN) CD4-CD8- (DN1, DN2, DN3) thymocytes were observed in
MK626-treated mice compared to controls after 4 and 6 weeks of treatment (S2A Fig).
No differences were observed between treated and control mice in the mean fluorescence
intensity (MFI) of the same subsets expressing CD26 (S2B Fig). Finally, no differences were
observed between groups in the percentage and CD26 expression on natural regulatory T cells
(Tregs) (CD4+CD25+FoxP3+) at any of the study’s time-points (S2C Fig). These results suggest
that the reduction of insulitis and the decrease in the incidence of T1D observed in
MK626-treated mice are not related to thymocyte subsets alterations in NODmice.
2. Peripheral compartments: Treatment with the DPPIV inhibitor MK626 increases the
expression of CD26 on CD8+ Effector memory T cells from both the spleen and pancreatic
lymph nodes
A. Spleen
First we aimed to ascertain whether treatment with MK626 had any effect on the percentage
of CD4+ and CD8+ T lymphocytes within the CD3+ population. No differences were observed
in the percentage of total CD4+ T cells nor in CD8+ T cells at any of the study’s time-points (4
and 6 weeks) between treated and control mice (S3A Fig). Moreover, the MFI for CD26 on
CD4+ and CD8+ T lymphocytes was similar in the two groups (S3B Fig).
Next, naïve, central and effector memory T cell (TCM and TEM) subsets were analyzed. No
differences were observed in the percentage of naïve, TCM, TEM, either in the CD4
+ or in the
CD8+ T cell subsets after 4 and 6 weeks of treatment with MK626 (Fig 3A). A representative
example of the multicolour flow cytometric analysis of naïve, TCM and TEM CD4
+ and CD8+ T
cell subsets in the spleen of control and treated mice at week 4 of treatment is shown in Fig 3B.
Then, we evaluated the CD26 expression on T cell subsets by MFI. The percentage of CD4+
and CD8+ T cells showing high density expression of CD26 (CD4+CD26high/CD8+CD26high)
was not studied due to the fact that there was not a clear subset delimitation after cytometric
analysis. After 4 and 6 weeks of treatment, the MFI of CD26 expression was significantly
increased on CD8+ TEM subset in NOD treated mice compared to controls (p = 0.002 at week
4; p = 0.03 at week 6) (Fig 3C). No differences were observed between treated and control mice
at any of the study time-points in the CD26 expression on the CD4+ TEM and naïve lympho-
cytes and TCM subset (CD8
+ and CD4+ subpopulations). Finally, MK626 treatment did not
modify the percentage and MFI of CD26 expression in CD4+ Tregs (CD4+CD25+FoxP3+)
(S3C Fig) nor in CD8+ Tregs (CD8+ CD122+PD-1+) at any of the analyzed time-points (data
not shown).
B. Pancreatic lymph nodes In addition, we investigated whether data observed in spleen was
replicated in PLNs after 4 weeks of treatment. No differences were observed in the percentage
of T cell subsets (naïve, TCM, TEM) between MK626-treated mice and controls (Fig 4A). In rela-
tion to CD8+ T cells, similar to the findings in spleen, we observed that the MFI of CD26
expression was significantly higher in the CD8+ TEM subset in NOD treated mice compared to
controls (p = 0.0004) (Fig 4B). Regarding CD4+ T cells, an increased expression of CD26 in
TEM subset was observed in the PLNs lymphocytes (p = 0.03). There were no significant differ-
ences between groups in CD26 expression on the naïve T cell and TCM subset (CD8
+/CD4+),
and neither in the conventional Tregs subsets (CD8+/CD4+) (data not shown).
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Fig 3. Effects of the DPPIV inhibitor MK626 on splenic T- lymphocytes. Splenocytes were obtained at 4 and 6 weeks after treatment. A) Percentage of T
effector memory (EM), T central memory (CM) and naïve T lymphocytes (CD8
+and CD4+) in control (white circles) and treated mice (black circles). B)
Representative FACS plots of the naïve (CD3+CD4+/CD8+CD44lowCD62L+), TCM (CD3
+CD4+/CD8+CD44highCD62L+) and TEM (CD3
+CD4+/
CD8+CD44highCD62Lneg) both for CD4+ and CD8+ T lymphocytes from spleen in treated and control mice at 4 weeks of treatment. C) MFI for CD26
expression on TEM, TCM and naïve T lymphocytes (CD8
+ and CD4+) in control (white circles) and treated mice (black circles). Lines represent the mean of
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Taken together, results obtained show that treatment with the DPPIV inhibitor MK626
increases the expression of CD26 in the CD8+ TEM cell subset, both in spleen as well as in PLNs
without affecting their percentage.
MK626 increases CD26 expression on CD8+ lymphocytes from
pancreatic islet infiltrate
To assess the mechanism through which DPPIV inhibitor treatment reduces insulitis and pre-
vents T1D in NODmice, the changes observed in T lymphocyte subsets obtained from the
pancreatic islet infiltrate were analyzed. Firstly, we evaluated whether treatment with MK626
had any effect on the percentage of CD4+ and CD8+ T lymphocytes infiltrating pancreatic
islets. There were no significant differences either in the percentage of CD4+ T cells or in CD8+
T cells between treated and control mice (Fig 5A). However, when CD26 expression on CD4+
and CD8+ T lymphocytes was evaluated, the MFI of CD26 expression was significantly
increased in the CD8+ subset, but not CD4 in MK626-treated mice compared to controls
(p = 0.05) (Fig 5B). These data show that, similar to what occurs with CD8+ TEM cells from
spleen and PLNs, DPPIV inhibitor MK626 increases the expression of CD26 in CD8+ T cells
from pancreatic islet infiltrate without affecting their percentage.
8–10 mice. Comparison between treated and untreated mice showed an increased expression of CD26 on CD8+ TEM cells at any of the study’s time-points.
(*p<0.05, **p<0.01, three way Anova).
doi:10.1371/journal.pone.0142186.g003
Fig 4. Effects of the DPPIV inhibitor MK626 on T lymphocytes from pancreatic lymph nodes (PLNs). T cells from PLNs were obtained from control
(white circles) and treated (black circles) NODmice at 4 weeks after treatment. A) Percentage of T effector memory (EM), T central memory (CM) and naïve T
lymphocytes (CD8+and CD4+). B) MFI for CD26 expression on TEM, TCM and naïve T lymphocytes (CD8
+and CD4+). The expression of CD26 was
significantly increased on CD4+ TEM and CD8
+ TEM cells in MK626-treated mice when compared to controls. Lines represent the mean of 6 mice (*p<0.05,
***p<0.001, three way Anova).
doi:10.1371/journal.pone.0142186.g004
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Expression of genes encoding for β-cell autoantigens after MK626
treatment
The expression of genes encoding for Ins2 (Insulin II) and Iapp (islet amyloid polypeptide) was
evaluated as markers of β-cell regeneration. Specific gene expression of α-cell mass and infil-
trating T lymphocytes was also determined. To that end, qRT-PCR was performed in the
whole pancreases of treated mice obtained at 4 weeks after treatment. As shown in Fig 6,
MK626-treatment in mice induces a tendency to increase expression of β-cell autoantigens
Fig 5. Percentage of T lymphocytes and CD26membrane expression in the leukocytic infiltrate of mice treated 4 weeks with MK626. A) Percentage
of CD8+ and CD4+ T lymphocytes infiltrating pancreatic islets in untreated (white circles) and treated (black circles) mice assessed by flow cytometry. Lines
represent the mean of 6–9 mice. No statistical differences were observed between groups (Mann-Whitney test). B) Expression of CD26 determined by flow
cytometry (MFI) in CD8+ and CD4+ T lymphocytes from control (white circles) and treated (black circles) mice. Lines represent the mean of 4–8 mice.
(*p0.05, Mann-Whitney test).
doi:10.1371/journal.pone.0142186.g005
Fig 6. β-cell specific gene expression in the islets of MK626 NOD treatedmice.Quantitative RT-PCR results for Ins2, Iapp,Gcg and CD45 genes in
control (white bars) and treated group (black bars) determined using Taqman assays. Gene expression signals were normalized toGadph. All data are
expressed as mean ± SD from 5mice. Significance was tested using Mann-Whitney test.
doi:10.1371/journal.pone.0142186.g006
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-Ins2 and Iapp- without changes in glucagon gene expression when compared to untreated
mice. Expression levels of CD45 were similar in both groups reflecting a similar insulitis score.
Effector memory CD8+ T cells from MK626-treated mice show enhanced
proliferative response and cytokine production in vitro
To investigate the T cell immune responsiveness of CD8+ TEM cells, an in vitro proliferation
assay was performed. Purified CD8+ TEM cells were isolated from spleen after 4 weeks of treat-
ment and were incubated with anti-CD3. Isolated CD8+ TEM lymphocytes from
MK626-treated mice showed an increased proliferative response in comparison to the control
group (p = 0.004) (Fig 7A). This CD8+ TEM cell expansion was accompanied by a significant
increase in secretion of IL-2 (p = 0.04), IL-4 (p = 0.02), IL-6 (p = 0.03), IL-10 (p = 0.01), IFN-γ
(p = 0.008) and TNF-α (p = 0.005) (Fig 7B). Remarkably, IL-4, IL-10, IFN-γ and TNF-α
showed the highest concentrations after stimulation. Moreover, MK626-treated mice displayed
a biological reduction of IL-17 and an increase of TGF-β secretion, although statistically non-
significant, when compared to control mice.
Taken together, these findings suggest that CD8+ TEM cells fromMK626-treated mice,
among which are included those with a high expression of CD26, show an increased capacity
of proliferative response and cytokine secretion.
Combination of effector memory CD8+ T cells and MK626 treatment
induces an immunosuppressive response in vitro
The suppressive effects of CD8+ TEM cells on T cell proliferation was determined in vitro, in
the presence or absence of the DPPIV inhibitor MK626. Initially, we proved that 10 μM of
MK626 did not alter the viability of splenocytes (data not shown). Then, CD8+ TEM cells were
isolated to investigate the immunosuppressive ability of CD8+ TEM cells, firstly in the absence
of MK626. Despite differences did not reach statistical significance, we observed a relevant bio-
logical effect. The percentage of proliferating T cells, stimulated with insulin-loaded mDCs,
was reduced by the presence of CD8+ TEM cells at different ratios (Fig 8A and 8B). Next, when
MK626 was added to co-cultures, we also observed a slight reduction in T cell proliferation at
any ratio. Interestingly, the percentage of T cell proliferation also tended to reduce only in the
presence of the DPPIV inhibitor MK626. Altogether, these data suggest that CD8+ TEM cells
and the DPPIV inhibitor MK626 tend to suppress antigen-stimulated T cell proliferation by
themselves, and support the immunosuppressive action of CD8+ TEM cells in the diabetogenic
autoimmune response of the NODmouse model.
Discussion
Immunomodulation and strategies aimed at redirecting deregulated immune pathways are
attractive lines of research in the field of T1D prevention. In the last decade several immune
therapies have focused on limiting both islet-reactive T cell immunity and β-cell death [27–30].
The present study demonstrates that targeting CD26 with the DPPIV inhibitor MK626 reduces
the incidence of T1D and insulitis degree in the pre-diabetic NODmouse model. The analysis
of peripheral and thymic T cell subsets shows that CD8+ TEM cells are the only T cell subset
affected by this treatment. More specifically, MK626 increases the expression of CD26 in CD8+
TEM lymphocytes as well as their proliferative capacity. Furthermore, our results suggest an
immunosuppressive action of CD8+ TEM cells that could be relevant in ameliorating autoim-
mune diabetes through DPPIV inhibitor treatment.
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Fig 7. Analysis of CD8+ TEM cell proliferation and cytokine production in vitro induced by MK626 treatment. CD8+ TEM cell from control (n = 9) and
treated (n = 9) mice obtained at 4 weeks of treatment were stimulated with anti–CD3 in vitro. A) Proliferative rate in CD8+ TEM lymphocytes from
MK626-treated mice (black circles) and in control group (white circles). T cell proliferation was expressed as counts per minute (c.p.m) using 3H-TdR. B)
Cytokine concentration (IL-2, IL-4, IL-6, IL-10, IL-12, IL-17, IFN-γ, TNF-α and TGF-β) in supernatant from proliferation assays in treated mice (black bars)
compared to control mice (white bars). Results are expressed as mean ± SEM. Mann-Whitney test was used for the evaluation of statistical significance
(*p<0.05;**p<0.01).
doi:10.1371/journal.pone.0142186.g007
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In our study, DPPIV inhibition by MK626 reduces the incidence of diabetes by 31%. Pre-
vention of T1D by targeting CD26 with the DPPIV inhibitor linagliptin has recently been dem-
onstrated in the NODmodel, with a reduction in T1D incidence of almost 50% [20].
Additionally, another DPPIV inhibitor has even been able to return hyperglycemic NODmice
to a normoglycemic state [21]. More recently, the combined treatment of low-dose monoclonal
anti-CD3 antibody and the same DPPIV inhibitor used in the present study, induces the remis-
sion of diabetes in new-onset diabetic NOD mice [31].
We found that insulitis score was significantly lower in MK626-treated mice than in con-
trols after 6 weeks of treatment. As expected, insulitis-free islets were more frequent in
MK626-treated than in control mice, showing the anti-diabetogenic effect of the DPPIV inhibi-
tor in NODmice. The reduction of insulitis concurs with other studies conducted in NOD
mice treated with DPPIV inhibitors [18,20,32]. No differences were observed in the insulitis
score at 4 weeks of treatment because it still corresponds to a relatively earlier phase of the pre-
diabetic state (10–12 weeks of age), whereas differences in insulitis observed at week 6 of treat-
ment (12–14 weeks of age) may be precluding the final protective effect of DPPIV inhibitor in
reducing the incidence of T1D. Potential modification of T lymphocyte migration has been
proposed as an explanation for such a protective effect, and in this respect, sitagliptin has been
shown to reduce T cell infiltration of grafted islets in the NODmouse and is associated with a
reduction in the in vitromigration of splenic and lymph node CD4+ T cells [19].
On the other hand, DPPIV inhibitor treatment demonstrated β-cell protective properties in
different animal models of T1D [20, 33–37]. Long term administration of a DPPIV inhibitor
increased the mass, replication and neogenesis of β-cells in streptozotocin-treated mice [35]. It
remains unclear whether these protective effects of DPPIV inhibition on β-cell mass are medi-
ated through incretins acting directly on β-cells increasing of endogenous GLP1 levels or
through incretin-independent effects. Recently, linagliptin administrated to non-diabetic NOD
mice, similarly to us, reduced insulitis, but no changes were observed in the Ki67 proliferation
index of β-cells, suggesting that the increased β-cells mass observed is not an incretin-mediated
Fig 8. Suppressive effect of MK626 and CD8+ TEM lymphocytes in vitro. A) Representative dot plots showing CFSE-T lymphocytes, stimulated with
insulin-loaded mDCs, in the presence or absence of CTV-CD8+ TEM lymphocytes (ratio 1:1) and MK626 (10μM). B) Percentage of proliferating CFSE
low T
lymphocytes versus all T lymphocytes, with insulin-loaded mDCs (circles and triangles), in the presence of CTV-CD8+ TEM lymphocytes (triangles) and
MK626 (open symbols) for 3 days. Plots show the mean (line) of three independent experiments.
doi:10.1371/journal.pone.0142186.g008
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effect, but rather a specific anti-inflammatory effect of DPPIV inhibition [20]. We have con-
ducted an approach based on transcriptomics, to determine the effect of DPPIV inhibitor
MK626 on β-cell regeneration. DPPIV inhibitor treatment tends to increase gene expression of
β-cell autoantigens (Ins2 and Iapp), suggesting that DPPIV inhibitors may possess cytoprotec-
tive and regenerative properties. Due to the fact that no clearly significant differences in GLP-1
concentrations were obtained between MK626-treated and control mice, it may indicate that
protective β-cell mass exerted by DPPIV inhibitor is based on immunomodulatory mecha-
nisms rather than incretin effects. Similar to findings described by other authors [20], it
appears that these immunoprotective effects are β-cell specific.
CD26 appears to play an important role in T cell development in the thymus. In fact, both
CD26 expression and DPPIV enzymatic activity are increased during thymocyte maturation
[38]. Thus, the administration of MK626 may indeed have effects on T cell development. In
the present study, treatment with MK626 did not change the percentage of thymocyte subsets
including SP CD4+, SP CD8+ DP and DN, nor CD26 expression between treated and control
mice. However, this does not rule out that an effect of MK626 on thymocytes may eventually
take place.
Regarding peripheral T cell subsets, the main finding of the present study is the increased
expression of the CD26 molecule in CD8+ TEM cell subset in treated mice. This effect was
observed in the peripheral lymphocytes beginning at week 4 of treatment. In the clinical set-
ting, the expression of CD26 has been analyzed in several peripheral blood T cell subsets in
patients with T1D in which a decreased expression of CD26 in CD8+ [12,39] as well as in
CD4+ T cells [39,40] have been described. These results suggest that decreased CD26 expres-
sion on several T cells subsets might represent a novel part of T lymphocyte regulatory dys-
function observed in T1D [39]. Few studies examined the effect of a DPPIV inhibitor
treatment on CD26 expression in human T lymphocyte subsets. In T2D, sitagliptin administra-
tion has been associated with decreased expression of CD26 in mononuclear cells [41] and con-
versely, in T2D patients not on DPPIV inhibitor treatment, CD26 expression was higher in
CD4+ and CD8+ T cells, although its expression was influenced by glycaemia [42]. In the pres-
ent study, NOD mice were treated in a pre-diabetic stage showing normal blood glucose levels,
thereby ruling out such a metabolic influence on CD26 expression.
In relation to CD8+ TEM cells, Morimoto et al have recently described that human CD8
+ T
cells that express CD26 at high levels belong to the subset of early effector memory T cells [43]
and studies conducted in virus infected patients suggest that these cells may be a marker of
effective long-term memory T cell formation [44]. In vitro studies show that in humans, CD8+
TEM cell-CD26-mediated co-stimulation has cytotoxic effects preferentially via granzyme B,
TNF-α, IFN-γ and Fas ligand (FasL) and this cytotoxic function is higher than what is obtained
with CD28-mediated co-stimulation.
In the present study, and in order to better characterize CD8+ TEM subset, a cell prolifera-
tion assay was performed using an anti-CD3 antibody. We hypothesize that the increased
expression of CD26 observed in this subset would account for a high proliferative rate of CD8+
TEM cells. In this regard, it has been reported that mesotelioma cells expressing high CD26 lev-
els display a higher proliferation activity than CD26 negative cells [45]. Results obtained in the
present study show that proliferation rate was higher in CD8+TEM cells from treated mice.
Moreover, cytokine analysis from supernatant of stimulated cells with CD3-monoclonal anti-
body showed a higher secretion of the anti-inflammatory cytokines IL-10 and IL-4 as well as
the pro-inflammatory cytokines IFN-γ and TNF-α in samples obtained from treated mice.
Effector memory T cells have been described to produce higher amounts of the cytokines IL-4
and INF-γ than central memory T cells [46], in accordance with our findings. The increase in
IFN-γ and TNF-α cytokines in the supernatant from CD8+ TEM stimulated cells in the present
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study may be explained by the presence of CD8+ TEM cells that express high levels of CD26
which are included in the CD8+ TEM cell pooling treated mice, given that these cells produce
high amounts of these two cytokines [43]. Moreover, levels of the anti-inflammatory cytokine
IL-10 were also increased in the supernatant of stimulated CD8+ TEM cells in treated mice,
assuming that another population of non-cytotoxic T cell may be actively secreting such cyto-
kine after MK626 plus anti-CD3. In this sense, in recent years several types of CD8+ T cell pop-
ulations have been described as exerting a regulatory suppressive action by virtue of mainly
three mechanisms: cell-to-cell contact mediated suppression, anti-inflammatory cytokine
secretion and cytotoxicity to the target cells [47], some of them involving the secretion of the
IL-10 [48] and some of them described as memory T cells [49,50]. In the present study, periph-
eral CD8 T cells were stained with the phenotypical markers CD122 and PD-1 in order to eval-
uate whether there were any differences in CD8+ Tregs between treated and control mice. No
differences were observed, although results should be taken with caution given the low percent-
age observed of this T cell subset. Thus, this doesn’t rule out the possibility that there may exist
a subset within the pool of CD8+ TEM cells in our experiments that has immuno-regulatory
properties. In fact, there is a recognized barrier while investigating CD8+ T suppressor cells due
to the lack of a recognized specific cell marker [46,49]. Nonetheless, and despite CD8+ Tregs
heterogenicity, there are several lines of evidence supporting the hypothesis that many Tregs
subsets share a memory-like phenotype suggestive of prior antigenic encounters [51,52]. On
the other hand, concerning classical Tregs such as CD4+CD25+Foxp3+ regulatory T cells, no
increase was observed in the periphery in the present study, in agreement with Cabrera et al
[32].
To further elucidate the immunoregulatory mechanism involved in the tolerance induction
observed after MK626 treatment, the regulatory potential of CD8+ TEM has been assessed in
the autoimmunity context of T1D. On one hand, the in vitro assay shows a suppressive func-
tion of CD8+ TEM on immune response and points to their possible anti-diabetogenic role in
the NODmouse model. On the other hand, the DPPIV inhibitor MK626 displays immunosup-
pressive effect by itself, according to other studies [18,53]. Due to the intrinsic suppressive
potential of CD8+ TEM, we believe that MK626 might not be able to strengthen the regulatory
effect of these cells in vitro. And, because MK626 treatment increases CD8+ TEM proliferative
capacity in our study, it is reasonable to speculate that CD8+ TEM cells have a role in tolerance
reestablishment lost in autoimmune diabetes. One way these effector cells may act is through a
cytotoxic action directed against cells that are involved in antigen presentation, thereby attenu-
ating the immune response. Additionally, a mechanism that cannot be discarded could also be
related to the presence of a T cell subset within the CD8+ TEM cell subset with immunoregula-
tory features due to its capacity to secrete IL-10.
Taking into account our results, future research should focus on analyzing the possible
mechanisms by which CD8+ TEM cells suppress the autoimmune response in diabetes.
Although the results of the present study suggest direct immunomodulatory effects of DPPIV
inhibition on T1D, a contribution of incretin modification or other additional factors that were
not evaluated cannot completely be ruled out.
In conclusion, treatment with the DPPIV inhibitor MK626 reduces insulitis and decreases
T1D incidence, concurring with a cytoprotective effect on β-cell mass. Furthermore, MK626
increases CD26 expression in the CD8+ TEM subset in lymphocytes from peripheral blood,
pancreatic lymph nodes and islet pancreatic infiltrate. Indeed, an immunosuppressive role for
CD8+ TEM cell subset in NODmice may be involved in the protection against autoimmunity to
β-cells. Our results provide more insights into the understanding of the mechanisms through
which targeting DPPIV/CD26 reestablishes β-cell tolerance.
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Supporting Information
S1 Fig. The effects of MK626 on plasma DPPIV activity and plasma active GLP-1 levels. A)
Histogram of the percentage of DPPIV inhibition in control (white bars) and treated (black
bars) mice after 2, 4 and 6 weeks of treatment. B) Levels of plasma active GLP-1 levels in con-
trol (white bars) and treated (black bars) mice after 2, 4 and 6 weeks of treatment; data repre-
sent mean ± SEM from 8 mice; no significant differences were found (MannWhitney test).
(TIF)
S2 Fig. Effects of MK626 on thymocytes subsets. A) Percentage of SP CD4+, single positive
(SP) CD8+, double positive (DP) and double negative (DN) in untreated (white circles) and
treated (black circles) mice. B) Expression (MFI) of CD26 on SP CD4+, SP CD8+, DP and DN
in control (white circles) and treated (black circles) after 4 and 6 weeks of treatment. C) Per-
centage (left) and MFI for CD26 expression (right) on natural Tregs (CD4+CD25+FoxP3+) in
control (white circles) and treated (black circles) mice at each checkpoint of the study. Lines
represent the mean of 8 mice. Comparisons between groups did not show significant differ-
ences (three-way ANOVA).
(TIF)
S3 Fig. Effects of MK626 treatment on splenic T-lymphocyte subsets from spleen after 4
and 6 weeks of treatment in control (white circles) and treated mice (black circles). A) Per-
centage of CD4+ and CD8+ T cells after 4 and 6 weeks of treatment in control (white circles)
and treated mice (black circles). B) MFI for CD26 expression on CD4+ and CD8+ T lympho-
cytes after 4 and 6 weeks of treatment in control (white circles) and treated mice (black circles).
C) Percentage (left) and MFI for CD26 expression (right) on Tregs (CD4+CD25+FoxP3+) in
control (white circles) and treated (black circles) mice at each time-point of the study. Lines
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